Pembrolizumab monotherapy: outcomes for PD-L1–positive (TPS ≥50%) metastatic NSCLC at USA oncology practices

Written by Rachel Jenkins, Senior Editor

In a new Publication Perspective, published in the Video Journal of Biomedicine, lead study author Vamsidhar Velcheti (New York University; NY, USA) summarizes his article, published in the journal Immunotherapy, on real-world outcomes associated with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%.

About the Video Journal of Biomedicine

The Video Journal of Biomedicine is a platform for authors to personally discuss their recently published paper in a short, high-quality, interview-style video. Each video allows authors to delve into their work in more detail, highlight its importance to the field and discuss its future implications. This enables viewers to gain a more comprehensive understanding of the publication.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.